维亚臻生物VSA012注射液启动II期临床 适应症为活动性狼疮肾炎等疾病

新浪财经
Jan 07

药物临床试验登记与信息公示平台数据显示,维亚臻生物技术(苏州)有限公司的评估VSA012注射液在中国活动性狼疮肾炎患者、原发性IgA肾病患者、C3肾小球病患者和免疫复合物介导的膜增生性肾小球肾炎患者中的有效性和安全性的多中心、开放设计的II期临床研究已启动。临床试验登记号为CTR20260041,首次公示信息日期为2026年1月7日。该药物剂型为注射剂,规格为120mg/1ml,用法用量为每3个月...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10